Showing results (81-90 of 320) with videos related to

Sort By:
Pageof 32
European Journal of Cancer & Clinical Oncology|April 1, 1984
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancerA L Harris, M Dowsett, I E Smith, et al.
Oncology|November 1, 1993
CVM versus ACE in the treatment of small cell lung cancerA L Jones, J Holborn, S Ashley, et al.
Clinical Oncology|June 1, 1983
Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapyR C Stuart-Harris, C A Mooney, I E Smith
British Journal of Cancer|March 1, 1987
The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patientsM Dowsett, A Lal, I E Smith, et al.
British Journal of Cancer|October 1, 1983
Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancerA L Harris, M Dowsett, I E Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1997
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)B Thürlimann, M Castiglione, S F Hsu-Schmitz, et al.
Cancer Practice|March 27, 2002
Integrating theory and practice. Conceptual frameworks of the CEFPH Preskill, D W Compton, M Baizerman, et al.
Clinical Immunology (Orlando, Fla.)|September 10, 2002
Express subcutaneous IgG infusions: decreased time of delivery with maintained safetyS Hansen, R Gustafson, C I E Smith, et al.
Cancer Treatment Reviews|December 1, 1983
Mitoxantrone (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancerI E Smith, R Stuart-Harris, N Pavlidis, et al.
The Pharmacogenomics Journal|June 25, 2014
Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trialV Le Morvan, S Litière, A Laroche-Clary, et al.
Pageof 32